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Abstract
Background: Loiasis is a major obstacle to ivermectin treatment for onchocerciasis control and lymphatic filariasis
elimination in central Africa. In communities with a high level of loiasis endemicity, there is a significant risk of severe
adverse reactions to ivermectin treatment. Information on the geographic distribution of loiasis in Africa is urgently needed
but available information is limited. The African Programme for Onchocerciasis Control (APOC) undertook large scale
mapping of loiasis in 11 potentially endemic countries using a rapid assessment procedure for loiasis (RAPLOA) that uses a
simple questionnaire on the history of eye worm.
Methodology/Principal Findings: RAPLOA surveys were done in a spatial sample of 4798 villages covering an area of
250063000 km centred on the heartland of loiasis in Africa. The surveys showed high risk levels of loiasis in 10 countries
where an estimated 14.4 million people live in high risk areas. There was a strong spatial correlation among RAPLOA data,
and kriging was used to produce spatially smoothed contour maps of the interpolated prevalence of eye worm and the
predictive probability that the prevalence exceeds 40%.
Conclusion/Significance: The contour map of eye worm prevalence provides the first global map of loiasis based on actual
survey data. It shows a clear distribution with two zones of hyper endemicity, large areas that are free of loiasis and several
borderline or intermediate zones. The surveys detected several previously unknown hyperendemic foci, clarified the
distribution of loiasis in the Central African Republic and large parts of the Republic of Congo and the Democratic Republic
of Congo for which hardly any information was available, and confirmed known loiasis foci. The new maps of the prevalence
of eye worm and the probability that the prevalence exceeds the risk threshold of 40% provide critical information for
ivermectin treatment programs among millions of people in Africa.
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Introduction
Loiasis is a neglected tropical disease caused by infection with
the filarial parasite Loa loa. It is an African disease restricted to the
equatorial rain forest regions of Central and West Africa [1,2,3,4].
The limits of its geographical distribution are Benin to the west,
Uganda to the east, latitude 10u to the north, and Zambia to the
south [5]. The disease is transmitted by Chrysops vectors with the
major species being C. silacea and C. dimidiata [6]. The clinical
manifestations of loiasis include sub-conjunctival migration of the
adult L.loa worm, oedema (Calabar swelling) and pruritus [7].
Loiasis has recently emerged as a disease of public health
importance, not because of its own clinical manifestations but
because of its negative impact on the control of onchocerciasis and
lymphatic filariasis in areas of co-endemicity. During the 1990s
several patients who harboured a high intensity of L.loa infection
developed severe adverse neurological reactions after treatment
with ivermectin for onchocerciasis in Cameroon [8,9]. Based on the
data forCameroon,a relationshipbetween theriskofsevereadverse
reactions and the intensity of L.loa infection was established and it
was estimated that individuals harboring more than 30000 L.loa
microfilaria per millilitre of blood (mf/ml) are exposed to a
significant risk of seriousneurological reactions following ivermectin
treatment [8,9,10]. The prevalence of high L.loa microfilarial loads
in endemic communities is directly related to the prevalence of
microfilaraemia, and it has been suggested that a microfilarial
prevalence of 20% in individuals above the age of 15 years be
regarded as the threshold above which there is an unacceptable risk
of severe adverse reactions (SAEs) with ivermectin treatment [11].
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reported [9], adequate knowledge was lacking on the geographic
distribution of loiasis. Boussinesq and Gardon undertook therefore
in 1997 a literature review of available data on the prevalence of
L.loa microfilaraemia in west and central African regions [12] and
identified several zones where loiasis was highly endemic and
overlapped with onchocerciasis, e.g. in parts of Cameroon, Gabon
and the Democratic Republic of Congo (DRC). However, the
available data were limited and there were many areas that were
potentially loiasis endemic but for which no local data on L.loa
infection existed. The published data also had limitations as they
were collected over different periods by different researchers using
non-standardized diagnostic procedures. Hence there was an
urgent need for more detailed, standardized information on the
distribution of loiasis in Africa as a basis for operational planning
of community directed treatment with ivermectin (CDTi) of
onchocerciasis and lymphatic filariasis.
Between 2000 and 2004, environmental risk models were
developed and applied for the prediction of loiasis endemicity
based on environmental factors (land cover, forest cover and soil
type in the initial model [13], and Normalised Difference
Vegetation Index or NDVI and elevation in later models
[14,15]) that were favorable for the development of Chrysops.
These models have helped to clarify the approximate distribution
of loiasis endemicity in Africa, but their predictions were not
always sufficiently precise [16]. Hence there was a need for local
epidemiological surveys in areas that were potentially loiasis
endemic and where ivermectin treatment was planned.
The standard parasitological method for the diagnosis of loiasis
is the thick blood film. However, this method is not very suitable
for large-scale surveys because of its invasiveness and operational
constraints. Immunological and molecular methods [17,18]
have been proposed for the diagnosis of loiasis, but have not
been sufficiently developed and tested to make them suitable
for large-scale epidemiological surveys. There was therefore an
urgent need for a non-invasive, simple and rapid method to
identify communities in which individuals are at risk of developing
SAEs.
A study carried out in Cameroon and Nigeria in 2001,
sponsored by the UNICEF/UNDP/World Bank/WHO Special
Program for Research and Training in Tropical Diseases (TDR),
led to the development of the Rapid Assessment Procedure for
Loiasis (RAPLOA) [19,20]. This method is based on a key clinical
manifestation of loiasis, the subcutaneous migration of the adult
L.loa worm under the conjunctiva of the eye, which is a well-
known and highly noticeable experience in loiasis endemic areas.
The study demonstrated a close correlation between the
prevalence of a history of eye worm and the prevalence L. loa
microfilaraemia at the community level. Using a threshold of 40%,
the prevalence of eye worm history was a good predictor of high-
risk communities, i.e. communities where the prevalence of
microfilaraemia .20% or where the prevalence of very high
intensities of infection (more than 30,000 mf/ml) .2%, with a
sensitivity of 100% and specificity ranging from 75 to 90% [20].
The RAPLOA method was subsequently validated successfully in
a study in the Republic of Congo and the Democratic Republic of
Congo ([21,22]). The Mectizan Expert Committee and the
Technical Consultative Committee of the African Programme
for Onchocerciasis Control (APOC) [23] jointly issued in 2004
guidelines for the treatment of onchocerciasis with ivermectin in
areas co-endemic for onchocerciasis and loiasis, and recom-
mended that RAPLOA be undertaken to assess the prevalence of
L.loa before commencing ivermectin distribution in areas suspect-
ed, or known, to be endemic for loiasis [24]. APOC subsequently
adopted RAPLOA for large-scale loiasis mapping in all potentially
endemic areas in APOC countries [25].
This article presents the results of the large-scale implementa-
tion of RAPLOA in the 11 APOC countries that were potentially
endemic for loiasis (Angola, Cameroon, Central African Republic,
Chad, Democratic Republic of Congo, Ethiopia, Equatorial
Guinea, Gabon, Republic of Congo, Nigeria and Sudan) and
presents a comprehensive map of loiasis as a basis for decision
making on ivermectin treatment for the control and elimination of
onchocerciasis and lymphatic filariasis in Africa.
Methods
Ethics statement
RAPLOA is based on a simple, non-invasive diagnostic method
using a short questionnaire, which was developed and validated by
the World Health Organization. The RAPLOA survey protocol
was reviewed by Technical Consultative Committee of APOC and
approved for loiasis mapping in Africa. The surveys in each
country were approved by, and undertaken under the authority of,
the Ministries of Health of the 11 African countries. Informed
consent was obtained from each respondent through a consent
procedure as described in the protocol. Each adult above the age
of 15 years in a selected household was individually briefed on the
objectives of the survey and informed that he/she was free to
participate or refuse. Informed consent was orally as many
respondents were illiterate. For those who refused to participate,
no further questions were asked and no information was recorded.
For those who consented, their name, age and years of residence in
the community were recorded before proceeding with the
RAPLOA interview.
1. RAPLOA
The surveys were conducted using the RAPLOA methodology
as described in the Guidelines for Rapid Assessment of L. loa [26].
This methodology consists of three steps:
N identification of local names for the L. loa eye worm using a
community-level questionnaire;
Author Summary
Loiasis is a neglected tropical disease caused by infection
with the filarial parasite Loa loa, transmitted by Chrysops
vectors. Loiasis has recently emerged as a disease of public
health importance when neurologic serious adverse events
(SAEs) were reported in individuals with high L. loa
microfilaraemia after ivermectin treatment. This had a
negative impact on the control of onchocerciasis and
lymphatic filariasis in areas of co-endemicity with loiasis.
Microfilarial prevalence of 20% has been suggested as the
threshold above which there is an unacceptable risk of
SAEs with ivermectin treatment.The African Programme for
Onchocerciasis Control (APOC) undertook large scale
mapping of loiasis in 11 potentially endemic countries
using a rapid assessment procedure for loiasis (RAPLOA)
that uses a simple questionnaire on the history of eye
worm. A geostatistical analysis method called kriging
applied to the results in 4798 sampled villages generated a
contour map of eye worm prevalence, providing the first
global map of loiasis based on actual survey data. This
map showed high risk levels of loiasis in 10 countries
where an estimated 14.4 million people live in high risk
areas.
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adults in the community, using an individual-level question-
naire which has three key questions;
N calculation of the percentage of adults who report a history of
eye worm, and, on the basis of this percentage, prediction of
the level of L. loa endemicity
At the beginning of the RAPLOA survey in each village, the
community questionnaire was administered to key informants
(village heads, headmasters, schoolteachers, health workers, patent
medicine dealers, traditional healers, and women and group
leaders) to determine the local names for the eye worm, the
population size and the number of households in the community.
After administration of the community questionnaire, the
geographic coordinates (latitude, longitude, altitude) of the
community were collected using a geographical positioning system
(GPS) unit in a central point or in front of the house of the village
chief.
Households to be included in the survey were then selected
randomly. The direction to start was determined by spinning a
bottle on the ground and selecting the direction in which the neck
of the bottle pointed when it came to a standstill. All adults in the
first household, fulfilling the criteria for inclusion - aged 15 years
and above, resident in the community for at least 5 years -were
interviewed, followed by all adults in the next household, and so
on until the required number of 80 individuals per community has
been reached. Some villages, notably in Equatorial Guinea, were
too small to reach the required sample size and in such villages all
adults were interviewed. However, when the total number of
adults in the village was less than 20, the village was excluded from
the analysis.
The individual questionnaire was designed to elicit responses on
experience of eye worm. Three key questions were asked
chronologically to collect data on the experience of eye worm.
The first question in each interview was ‘‘Have you ever experienced or
noticed worms moving along the white of the lower part of your eye ?’’. After
recording the response, the interviewer then showed a photograph
of the eye worm to each respondent, guided him/her to recognize
the worm on the photograph and then asked the second question:
‘‘Have you ever had the condition in this picture?’’. After recording the
answer, the interviewer proceeded to ask the third question: ‘‘The
last time you had this condition, how many days did the worm last before
disappearing?’’.
A respondent was classified as having a history of eye worm
when the answers to the first two questions were positive and the
duration in the third question was less or equal to 7 days. For each
village the percentage of respondents with a history of eye worm
was computed to give the prevalence of history of eye worm.
2. Sampling
In each country, villages for the survey were selected in areas
that were potentially endemic for loiasis. The surveys were
conducted in two phases
Phase 1: 2002–2006: During this period, RAPLOA surveys
were conducted in areas that were earmarked for ivermectin
treatment for onchocerciasis control by APOC and that were
located in areas that were potentially endemic for loiasis. Only
areas that were meso or hyper endemic for onchocerciasis were
targeted.
Phase 2: 2008–2010: with the increasing expansion of NTDs
programmes that included the distribution of ivermectin for the
elimination of lymphatic filariasis, there was an urgent need by
country programmes and partners to have a better knowledge of
the distribution of loiasis throughout the African region, including
in areas that were not targeted for onchocerciasis control. After it
was mandated by its board, the Joint Action Forum, APOC
undertook to complete the RAPLOA surveys in the areas outside
the onchocerciasis endemic areas not yet covered by RAPLOA
surveys.
In every target area, villages were selected with a random spatial
sampling procedure to ensure good geographical coverage of the
area. The distance between sample villages was around 10 km
during phase 1, but when the results of phase 1 showed that the
distribution of loiasis was much less localised than initially thought
and that there was strong spatial correlation in eye worm
prevalence over distances up to 100–200 km, the distance between
sample villages was gradually increased to about 25 km during the
last round of surveys of phase 2. Villages were selected using the
Healthmapper software and data base (http://www.who.int/
health_mapping/tools/healthmapper) or a 1:200,000 scale local
paper map of the area.
3. Data processing
Data entry was mostly performed by the survey teams at
country level using Microsoft Excel@ but sometimes at APOC
headquarters using SPSS data entry builder@. Only aggregate
village level data were entered: total population, number
interviewed, number and percentage with eye worm history and
location information, i.e. GPS readings of latitude and longitude,
name of village, names of all administrative levels. When
RAPLOA results were received at APOC headquarters, systematic
data checking was undertaken including the validation of
geographical coordinates (latitude, longitude) of all surveyed
villages using geographical information system software (Atlas*-
GIS
@, ArcGIS
@). Where available, the geographic coordinates of
survey villages were compared to the coordinates found in the
GADM database of the Global Administrative Areas (http://www.
gadm.org, email: ). All RAPLOA data were then integrated into a
master database in Microsoft Access
@ at APOC headquarters.
4. Spatial analysis
The survey data were first analyzed using SPSS version 15
(www.spss.com) to generate summary tables and bar charts on the
survey activities by country and year. The geographical informa-
tion system software ArcGIS version 10 (ESRI Inc., Redlands,
USA) was used for spatial analysis of the RAPLOA data. The
prevalence of history of eye worm for each village was submitted to
a logit transformation. The transformed prevalence data were then
analyzed through a geostatistical method called kriging using the
Geostatistical Analyst Extension of ArcGIS v10. The kriging
analysis involved variography to determine the spatial correlation
pattern in the survey data and a process of weighted spatial
smoothing to predict the distribution of the logit prevalence
throughout the surveyed area. Kriging gives a predicted
prevalence at any location, but with poor precision at large
distances from the sampled locations. We therefore defined the
‘‘surveyed area’’ pragmatically as the area where the local
prediction standard error was smaller than, or equal to, the
average standard error obtained in the cross validation analysis of
the difference between predicted and observed logit prevalences
for the surveyed villages. This definition ensured that the
‘‘surveyed area’’ covers all surveyed villages but does not extend
beyond a distance of 40 to 100 km from the nearest surveyed
village. For each location in the surveyed area, the predicted
probability that the true prevalence exceeds 40% was estimated by
calculating Z={(logit(0.4)2M)/S, where M is the local predicted
logit prevalence and S the prediction standard error, and using the
normal distribution to determine the corresponding probability.
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original scale to produce prevalence and probability contour maps
for the surveyed area.
The contour map was also used to estimate the proportion of
each country surface that was mapped by RAPLOA, and to divide
the mapped surface into 4 loiasis endemicity classes with
prevalence of eye worm 0–4%; 5–19%; 20–39% and .=40%.
The rural population in each class was tentatively estimated as the
total rural population for the country multiplied by the proportion
of country surface falling in that class, assuming a uniform
distribution of the rural population in the country. These estimates
will be refined when a detailed population density map for the
Table 1. Number of villages surveyed and number of people interviewed in 11 APOC countries.
Country
No. villages
surveyed
No. of people
interviewed
Mean no.
interviewed per
village
No. interviewed
who had history
of eye worm Percentage with eye worm history per village
Minimum Median Maximum
ANGOLA 222 18,589 83.7 2,822 0.0 5.6 98.8
CAMEROON 812 66,996 82.5 28,622 0.0 0.0 98.8
CAR 173 13,874 80.2 6,310 0.0 47.5 95.6
Chad 111 8,876 80.0 913 0.0 0.0 87.5
CONGO 195 14,666 75.2 6,647 0.0 50.0 100.0
DRC 2,516 199,766 79.4 42,710 0.0 13.8 86.3
EQUATORIAL GUINEA 84 4,907 58.4 3,208 11.8 70.9 100.0
ETHIOPIA 28 2,240 80.0 0 0.0 0.0 0.0
Gabon 65 5,015 77.1 3,263 23.6 66.3 95.0
NIGERIA 381 30,106 79.0 5,708 0.0 18.8 69.5
SUDAN 211 16,540 78.4 3,138 0.0 10.0 93.0
Total 4,798 381,575 79.6 103,341 0.0 20.8 100.0
doi:10.1371/journal.pntd.0001210.t001
Figure 1. Number of villages surveyed for RAPLOA by country and year.
doi:10.1371/journal.pntd.0001210.g001
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the surface (in square kilometers) of the 11 African countries were
obtained from the GADM database of Global Administrative
Areas (http://www.gadm.org). The total rural population for each
of the 11 countries was extracted from the database of the United
Nations department of Economic and Social Affairs (http://esa.
un.org/unpd/wpp2008/tab-sorting_population.htm).
Results
RAPLOA surveys were undertaken in a total of 4798 villages in
the 11 APOC countries that were known or suspected to be
endemic for loiasis (see table 1). In 10 countries, the RAPLOA
surveys confirmed the presence of loiasis and in each of these
countries there were high risk villages where 69% to 100% of those
interviewed reported a history of eye worm. In Equatorial Guinea
and Gabon, eye worm was reported from all surveyed villages.
Only in Ethiopia did none of the respondents report a history of
eye worm.
The surveys were done in two major phases between 2002 and
2010 (figure 1). The first phase from 2002 to 2006 was triggered by
the occurrence of SAEs after ivermectin treatment in Cameroon
and DRC, and the urgent need of CDTi projects in these two
countries to understand the local endemicity of loiasis and the
corresponding risk of SAEs. The need for such information was
especially great in DRC where a large number of CDTi projects
were to be launched around that time. A major survey effort was
therefore undertaken in 2005 during which as many as 1,771
RAPLOA surveys were done in DRC alone. The second major
survey effort was in 2010 after APOC undertook to complete the
RAPLOA mapping in Africa, including in areas not targeted for
onchocerciasis control but that were of importance for lymphatic
filariasis elimination with ivermectin treatment. This second effort
filled several remaining gaps in the survey coverage of the total
area in Africa where loiasis is potentially endemic.
The locations of the survey villages and the boundaries of the
‘‘surveyed area’’ are shown in figure 2. The geographic
distribution of survey villages is not uniform and in Cameroon
and DRC there are some areas with a heavy concentration of
surveyed villages. This reflects the intensified efforts of 2003 to
2005 in response to urgent survey needs of specific CDTi projects
in those areas. In subsequent years, and particularly in 2010, a
grid-based sampling method was introduced to select RAPLOA
survey villages at more regular distances to ensure better spacing of
the sample. Altogether, the RAPLOA survey villages cover a vast
area of some 2500 km63000 km centred on the heartland of
loiasis in central equatorial Africa.
The spatial analysis of the RAPLOA data showed a strong
spatial correlation pattern. This is illustrated in the variogram in
figure 3 which shows the semi-variance, a measure of the variation
in prevalence data in relation to the distance between survey
villages. At short distances, the semi-variance is small, indicating
that villages that are located closely together tend to have similar
prevalences of history of eye worm. With increasing distance, the
Figure 2. Geographical distribution of RAPLOA surveyed villages in 11 APOC countries.
doi:10.1371/journal.pntd.0001210.g002
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declines. This spatial correlation pattern has been modeled as
shown by the solid line in figure 3 (spherical model with range 5,
nugget 0.477 and sill 2.6345). This model was subsequently used in
a kriging analysis of the RAPLOA data to produce, through a
process of spatial smoothing, a map of the prevalence of eye worm
history throughout the surveyed area.
Figure 4 shows the results of the kriging analysis. This map
provides the best estimate of the geographic distribution of loiasis
based on the RAPLOA data. The main geographic pattern is
clear. There are two zones of highly endemic loiasis: a western
zone that comprises the totality of the continental part of the
Equatorial Guinea and Gabon, Cameroon south of 6uN, and parts
of the Republic of Congo, the Central African Republic and
Chad. This western zone also comprises the Mayombe forest in
the west flank of the Bas-Congo province in the DRC and the
Cabinda and west of Bengo provinces in Angola. The second
hyper-endemic zone is mainly made up of the North-Eastern part
of the Democratic Republic of Congo. It has its epicenter in the
Province Orientale with extensions towards the Equateur province
in the west, Maniema province in the south and Sudan in the
north-east. There are also vast areas where there is no loiasis or
where its endemicity is very low, e.g. in most of DRC, north
Cameroon and large sections of Angola, Nigeria, Chad and
Sudan. In between there are some intermediate zones where the
estimated prevalence of eye worm history ranges between 20 and
40%.
The estimates given in figure 4 involve statistical uncertainty
which is important to take into account, especially around the
policy threshold value of a prevalence of 40% eye worm history.
Figure 5 therefore provides a map of the predicted probability that
the local prevalence of eye worm history exceeds 40%. In most of
the surveyed area, there appears to be little uncertainty and the
probability that the prevalence exceeds the threshold is whether
very high (.0.9) or very low (,0.1). Hence, these results
strengthen the above conclusion with respect to areas with very
high and very low endemicity. However, in some intermediate
areas, the results are less clear-cut. In such areas it will be
important to inspect the available data in greater detail to assess
the operational implications of the RAPLOA findings for local
ivermectin treatment programs.
As an example of this process, figure 6 provides a detailed map
of the border area of Chad, Cameroon and the Central African
Republic (CAR). In south Chad the RAPLOA data revealed the
existence of a previously unknown focus of hyperendemic loiasis.
Across the border in CAR the spatial analysis showed a vast area
Figure 3. Semi-variance of the prevalence of history of eye worm in relation to distance between survey villages.
doi:10.1371/journal.pntd.0001210.g003
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very high for all surveyed villages. In the centre of the map,
between these two hyperendemic areas, there is a zone for which
the RAPLOA prevalence data are between 20% and 40% and
which the kriging analysis has classified as intermediate and below
the risk threshold of 40%. Nevertheless, being so close to two
highly endemic zones, it might be prudent in such a borderline
area to take the same precautionary measures as in the
surrounding highly endemic areas when implementing ivermectin
treatment. Such a strategy might also be operationally more
convenient if the intermediate and high endemicity groups of
villages fall under the same implementation unit of the health
system.
Table 2 shows the result of an attempt to estimate the
population at risk in the different countries using the RAPLOA
map. Five countries, Cameroon, Congo, DRC, Equatorial Guinea
and Gabon, have been nearly completely mapped for loiasis. The
other six countries were only partly covered by RAPLOA surveys.
Some regions were purposely excluded because they were known
to be loiasis free, e.g. the desert regions of Chad and Sudan. The
North East of CAR and the bordering area in Sudan could not be
surveyed because of security reasons while the mapping of Angola
is not yet complete. However, the vast majority of potentially
loiasis endemic areas in Africa have been mapped.
Table 2 shows a breakdown of the mapped area by loiasis
endemicity level. Equatorial Guinea and Gabon are the most
endemic countries where nearly the whole area falls into the high
risk category with more than 40% RAPLOA prevalence. In DRC,
only 18% of the area falls into this category but because of its
much larger population, this translates into an estimated
population of 7.4 million people living in high risk areas. In terms
of population at high risk, Cameroon comes second with 4 million
people. DRC and Cameroon together account for 80% of the
estimated 14.4 million people living in high risk areas.
Discussion
The RAPLOA surveys represent a major effort of the African
Programme for Onchocerciasis Control in response to a serious
operational challenge for onchocerciasis control and lymphatic
filariasis elimination. Within two periods of a few years, thousands
of rapid assessment surveys were done in order rapidly to generate
the local data on loiasis endemicity levels that were needed for
planning of ivermectin treatment in potential loiasis areas. The
surveys were undertaken by the Ministries of Health in the affected
countries, with technical and financial support from APOC. The
technical support, provided by a group of African experts, has also
contributed to strengthening national capacity for epidemiological
evaluation and surveillance.
Initially, the RAPLOA surveys targeted areas where CDTi
projects were planned and where information on loiasis endemic-
ity was urgently needed. These CDTi projects needed to
understand the local risk of adverse reactions to guide decision
making on appropriate measures for monitoring and management
Figure 4. Map of the estimated prevalence of eye worm history in Africa.
doi:10.1371/journal.pntd.0001210.g004
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Mectizan Donation Program. As the RAPLOA survey data
accumulated, the beginning of a loiasis map began to emerge. The
final round of surveys in 2010 filled most of the remaining gaps in
survey coverage and a comprehensive evidence-based map of
loiasis is now available that covers most of the potentially loiasis
endemic area in the world. The only large areas that remain to be
mapped are a border area between CAR and Sudan, which has a
low population density but is likely to be highly endemic for loiasis,
and much of Angola, where loiasis may not be widespread.
Beyond the APOC countries, loiasis is rare; one focus of low
endemicity is known in south Benin, and a few sporadic cases
reported from Zambia [12].
The resulting map of the prevalence of eye worm history is
unique and provides the first global map of loiasis based on actual
survey data. The map shows a clear geographic distribution of
loiasis with two zones of hyper-endemicity, large areas that are free
of loiasis or of low endemicity, and several borderline or
intermediate zones including one zone in north-west DRC that
bridges the two hyper-endemic zones. The implications for
ivermectin treatment are evident: in the hyper-endemic zones
there is a high risk of SAEs and special precautionary measures are
required in accordance with the MDP guidelines [16,24]. For the
loiasis-free and low endemic areas no special measures are
required and ivermectin treatment can be implemented without
risk. The intermediate zones will generally require more detailed
assessment of the available data, as demonstrated above by the
example for South Chad, in order to support local decision-
making on ivermectin treatment. APOC will therefore make the
necessary detailed maps available to endemic countries and their
partners in onchocerciasis control and lymphatic filariasis
elimination, and publish these maps on its website (www.who.
int/apoc). The data for Chad also provide a good example of
important new information that has become available through the
RAPLOA surveys. It is always been assumed on the basis of few
data that loiasis was rare and of very low endemicity in Chad
[12,27,28,29] and the discovery of a hyperendemic focus in the
southern part of this country was a surprise. Similarly, RAPLOA
has clarified the distribution of loiasis in the Central African
Republic and large parts of Congo and DRC for which hardly any
information was available previously.
In addition to providing important new information on the
distribution of loiasis, the RAPLOA surveys have confirmed the
continued existence of known loiasis foci in several countries ([12].
In Cameroon the previously documented L. loa foci in the south
region [30], the centre region [31], Adamaoua region [32],
Littoral region [30,33], and the south-west region [1] have all been
confirmed. New foci have been revealed in the North West and
Adamaoua regions situated in savannah areas that were not
known to be endemic for loiasis. In Nigeria, the RAPLOA surveys
indicate that the level of endemicity of loiasis is relatively low. The
most affected areas are south of latitude 6uN, between the Niger
delta and the border with Cameroon, which is in conformity with
previous knowledge [34,35,36]. For the Central African Republic,
Figure 5. Map of the predictive probability that the local prevalence of eye worm history exceeds 40%.
doi:10.1371/journal.pntd.0001210.g005
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doi:10.1371/journal.pntd.0001210.g006
Table 2. Estimated areas and population at risk for loiasis in 11 APOC countries.
Percentage of mapped area
by Prevalence of eye worm
Rural population (61000) by
Prevalence of eye worm
Country
Rural
population
(61000)
Area country
(km2)
Area mapped
(km2)
%
mapped
Rural
population
in mapped
area
(61000)
0%–
4.9%
5%–
19.9%
20%–
39.9%
40%–
100% 0%–4.9%
5%–
19.9%
20%–
39.9%
40%–
100%
Angola 7 881 1 252 421 427 714 34% 2 691 66,6 20,9 6,8 5,7 1 792 563 183 153
Cameroon 8 303 466 307 451 857 97% 8 046 27,8 11,2 10,9 50,2 2 234 900 873 4 038
CAR 2 751 621 499 445 381 72% 1 971 4,8 20,8 29,1 45,3 95 410 573 893
Chad 8 328 1 168 002 326 493 28% 2 328 80,0 11,9 6,0 2,1 1 862 276 141 49
Congo 1 424 345 430 344 685 100% 1 421 3,5 21,2 22,8 52,5 497 301 324 746
DRC 43 940 2 337 027 2 215 074 95% 41 647 43,3 22,8 16,2 17,7 18 017 9 510 6 743 7 377
Eq. Guinea 418 27 085 26 950 99% 416 0,0 0,0 7,6 92,4 0 0 31 384
Ethiopia 70 818 1 132 328 82 460 7% 5 157 100,0 0,0 0,0 0,0 5 157 0 0 0
Gabon 210 261 689 260 764 100% 209 0,0 0,1 2,6 97,3 0 0 6 204
Nigeria 79 441 912 039 278 233 31% 24 235 20,6 54,8 23,5 1,0 4 997 13 281 5 703 254
Sudan 25 871 2 490 410 511 017 21% 5 309 64,3 18,4 12,4 4,8 3 416 977 658 257
Grand
Total
249 385 11 014 237 5 370 628 93 430 40% 20% 15% 25% 37 621 26 218 15 235 14 357
doi:10.1371/journal.pntd.0001210.t002
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have shown that loiasis is highly endemic in the south west and
south east of the country. In the Democratic Republic of Congo,
the well known highly endemic focus of Mayombe in the most
western part of Bas-Congo province and of Ueles in the North-
eastern part of province Orientale ([38,39] have also been
confirmed.
The main endemicity pattern as shown on the RAPLOA map is
broadly similar to the pattern on the map produced by Thomson
et al [13] using an environmental risk model which also shows high
endemicity in the West and the East, and a zone of lower
endemicity in between. However, there are also major discrepan-
cies between the two maps. The environmental risk map predicts
the highest endemicity in Congo and south-west DRC, but the
RAPLOA survey showed that endemicity levels in both areas were
very low. Conversely, the map of Thompson et al suggests that the
Central African Republic is largely loiasis free while the RAPLOA
surveys showed a very high endemicity level throughout nearly
half the country. Hence the environmental risk models, though
useful for showing general trends, are not reliable enough for use
in operational decision making for ivermectin treatment. Diggle et
al [15] subsequently developed a spatial statistical model that
incorporated the environmental risk variables NDVI and
elevation, for the analysis of epidemiological survey data on the
prevalence of L.loa microfilaraemia. The application of this model
to prevalence data for Cameroon showed a significant improve-
ment over the Thompson model. However, a comparison with the
RAPLOA map showed that model predictions at more than
100 kilometres from the nearest survey village were sometimes also
very inaccurate. One possible explanation is that NDVI and
elevation have only limited predictive value on their own, as
suggested by the low correlation between these environmental
variables and the prevalence of MF [14,15]. Using the results of a
calibration analysis of the relationship between the prevalence of
RAPLOA and the prevalence of MF, the RAPLOA data are now
being incorporated into the spatial statistical model in order to
enhance its predictive value.
On the basis of the RAPLOA results, it is tentatively estimated
that some 14.4 million people live in high risk areas where the
estimated prevalence of eye worm history is greater than 40%, and
15.2 million in intermediate areas with estimated eye worm
prevalences between 20 and 40%. The number of people at high
risk varies considerably between countries. Nearly the whole
country of Gabon is classified as high risk, and represents a large
proportion of the total high risk area in Africa, but because of the
low population density in Gabon it represents less than 2% of the
total high risk population. DRC with 7.4 million and Cameroon
with 4 million represent together 80% of the estimated total
population at high risk.
Not all highly endemic loiasis areas overlap with the geographic
distribution of onchocerciasis or lymphatic filariasis but in most of
the surveyed countries there is considerable overlap and thus a
significant risk of SAEs with ivermectin treatment. The map of the
prevalence of eye worm therefore provides critical information for
ivermectin treatment programs among millions of people in
Africa. This information comes particularly timely for lymphatic
filariasis elimination for which loiasis has been a major barrier in
Central Africa [40] but which can now go ahead in the many areas
where loiasis endemicity is low or nil.
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